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SHORT COMMUNICATION
Acrodermatitis continua of Hallopeau (ACH) is a rare, 
chronic disease characterized by acropustular eruptions 
predominantly involving the distal phalanges of the hands 
and feet with marked involvement of the nail bed. The 
sterile pustules may coalesce to form groups of lesions, 
which, over time, may spread proximally to involve the 
dorsal side of the hands, forearms and feet. Pustulation 
of the nail bed and nail matrix are often associated with 
onychodystrophy and even anonychia of the involved 
digits. Atrophic skin changes, onychodystrophy and 
osteolysis are frequently present, causing painful and 
disabling lesions (1).
CASE REPORT 
A 9-year-old girl (body mass index (BMI) 18.9) presented to 
our department with a 3-year history of ACH, with recurrent 
flares of painful pustular scaly lesions on the distal portion of 
the fingers and toes, with associated severe onychodystrophy 
(palmoplantar pustular psoriasis area and severity index (PP-
PASI) score 62) (Fig. 1A). No other lesions were noted over the 
patient’s body surface area. Her past medical history was other-
wise unremarkable, with no thyroid dysfunction and no family 
history of psoriasis. Clinical and microbiological examination 
did not show any bacterial or fungal infection. Histological 
features of psoriasis were found in a biopsy specimen from 
skin lesion. X-ray examination revealed no osteolytic changes 
of the bones and no joint deformities. Based on the clinical and 
histopathological findings, ACH was confirmed. 
Previous treatments with potent topical corticos-
teroids, cyclosporine (3 mg/kg/day for 6 months) 
and etanercept (0.4/kg/twice a week for 3 months) 
had all been unsuccessful. Because of the lack of 
efficacy of previous therapies and severe disability, 
we decided to use the human anti-tumour necrosis 
factor alpha (anti-TNFα) monoclonal antibody ada-
limumab. After receiving approval from the local 
ethics committee, adalimumab was introduced at 
a first dose of 80 mg, 40 mg after 1 week and then 
40 mg every other week. After the first 4 weeks of 
treatment, a substantial improvement in the lesions 
was noted, without formation of pustules, leaving 
only mild onychodystrophy (PPPASI score 6) (Fig. 
1B). At 8 weeks of treatment there was complete 
resolution of the clinical aspects. The effects of 
adalimumab persist after 12 months of therapy, with 
no adverse events, relapse or need for additional 
treatment. The young patient currently remains 
under treatment and follow-up.
DISCUSSION
ACH is generally considered as a rare variant 
of pustular psoriasis, though some authors 
classify it as a separate entity. Histology 
shows neutrophils filling the subcorneal ca-
vity and aggregations of leukocytes between 
the epidermal cells forming spongiform 
pustules (of Kogoj), with a lymphohistiocytic 
infiltrate and focal oedema of the superficial 
dermis (2). The disease runs a chronic, relap-
sing course with slow proximal progression 
and may evolve into generalized pustular 
psoriasis. It is more common in middle-aged 
females and often begins after localized 
trauma (3), but is rare in children. The disease 
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Fig. 1. Palmar involvement at baseline (A). Complete resolution of lesions after 8 weeks 
of treatment (B).
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is difficult to treat, with limited success reported with 
numerous agents, including topical treatment such as 
corticosteroids, tar, dithranol, fluorouracil, calcipotriol 
and calcineurin inhibitors (4), phototherapy (5), cy-
closporine, methotrexate combined with oral propylt-
hiouracil (6), retinoids (7), dapsone (8), thalidomide in 
association with ultraviolet (UV) (9) and tetracyclines 
(10). Recently, there have been reports of effective 
treatment with the biologic agents infliximab (11) and 
etanercept (12). Sopkovich et al. (13) described success-
ful treatment of ACH with adalimumab. In childhood the 
treatment can be a challenge because many therapeutic 
options have drawbacks or are not approved. We report 
here the case of a 9-year-old female patient who was 
treated successfully with adalimumab.
Adalimumab is a recombinant, fully human, anti-
TNF-α monoclonal IgG1 antibody that acts primarily 
by binding both soluble and cell-bound forms of TNF-α 
and neutralizing the activity of cytokine (14). TNF-α 
blockers have shown efficacy in refractory ACH, sup-
porting the relationship of TNF-α to this kind of disorder 
(15). Since our case is a paediatric patient, double-blind, 
placebo-controlled trials would be desirable to ascertain 
the safety and efficacy of this treatment.
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